These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16005470)

  • 21. Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis: a comparison with heparin.
    Sudo Y; Lucchesi BR
    J Cardiovasc Pharmacol; 1996 Apr; 27(4):545-55. PubMed ID: 8847872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antithrombin is as effective as heparin and hirudin to prevent formation of microvascular thrombosis in a murine model.
    Sorg H; Hoffmann JN; Menger MD; Lindenblatt N; Goehring P; Vollmar B
    Thromb Haemost; 2006 Sep; 96(3):371-7. PubMed ID: 16953281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjunctive Therapy with an Antithrombotic Drug Can Prevent Reocclusion and Induce Residual Thrombus Reduction After Percutaneous Transcatheter Angioplasty of the Thrombotic Lesions.
    Kawano H; Tomaru T; Omata M; Okada R; Uchida Y
    J Thromb Thrombolysis; 1997; 4(2):293-300. PubMed ID: 10639273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiplatelet effect of FK633, a platelet glycoprotein IIb/IIIa antagonist, on thrombus formation and vascular patency after thrombolysis in the injured hamster carotid artery.
    Kaida T; Matsuno H; Niwa M; Kozawa O; Miyata H; Uematsu T
    Thromb Haemost; 1997 Mar; 77(3):562-7. PubMed ID: 9066011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model.
    Roux S; Tschopp T; Baumgartner HR
    J Pharmacol Exp Ther; 1996 Apr; 277(1):71-8. PubMed ID: 8613969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.
    Nielsen VG; Steenwyk BL; Gurley WQ; Pereira SJ; Lell WA; Kirklin JK
    J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of antithrombotic activity of heparin, ASA, sulfinpyrazone and VK 744 in a rat model of arterial thrombosis.
    Philp RB; Francey I; Warren BA
    Haemostasis; 1978; 7(5):282-93. PubMed ID: 689491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antithrombotic efficacy of low-molecular-weight heparin in deep arterial injury.
    Heras M; Chesebro JH; Webster MW; Mruk JS; Grill DE; Fuster V
    Arterioscler Thromb; 1992 Feb; 12(2):250-5. PubMed ID: 1311947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time.
    Sato K; Kawasaki T; Taniuchi Y; Hirayama F; Koshio H; Matsumoto Y
    Eur J Pharmacol; 1997 Nov; 339(2-3):141-6. PubMed ID: 9473127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats.
    Feuerstein GZ; Patel A; Toomey JR; Bugelski P; Nichols AJ; Church WR; Valocik R; Koster P; Baker A; Blackburn MN
    Arterioscler Thromb Vasc Biol; 1999 Oct; 19(10):2554-62. PubMed ID: 10521387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Troubleshooting the rabbit ferric chloride-induced arterial model of thrombosis to assess in vivo efficacy of antithrombotic drugs.
    Couture L; Richer LP; Mercier M; Hélie C; Lehoux D; Hossain SM
    J Pharmacol Toxicol Methods; 2013; 67(2):91-7. PubMed ID: 23231926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contribution of von Willebrand factor to thrombus formation on neointima of rabbit stenotic iliac artery under high blood-flow velocity.
    Yamashita A; Asada Y; Sugimura H; Yamamoto H; Marutsuka K; Hatakeyama K; Tamura S; Ikeda Y; Sumiyoshi A
    Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1105-10. PubMed ID: 12750116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative intravenous antithrombotic actions of heparin and site directed thrombin inhibitors in a jugular vein clamping model.
    Hayes JM; Jeske W; Callas D; Iqbal O; Fareed J
    Thromb Res; 1996 Apr; 82(2):187-91. PubMed ID: 9163072
    [No Abstract]   [Full Text] [Related]  

  • 35. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
    Rebello SS; Bentley RG; Morgan SR; Kasiewski CJ; Chu V; Perrone MH; Leadley RJ
    Br J Pharmacol; 2001 Aug; 133(7):1190-8. PubMed ID: 11487531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo dynamic real-time monitoring and quantification of platelet-thrombus formation: use of a local isotope detector.
    Zaman AG; Osende JI; Chesebro JH; Fuster V; Padurean A; Gallo R; Worthley SG; Helft G; Rodriguez OX; Fallon JT; Badimon JJ
    Arterioscler Thromb Vasc Biol; 2000 Mar; 20(3):860-5. PubMed ID: 10712414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
    Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
    Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
    Elg M; Gustafsson D; Deinum J
    Thromb Haemost; 1997 Oct; 78(4):1286-92. PubMed ID: 9364999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [An experimental study of arterial graft implantation--the effects of an anti-thrombin agent, argatroban, and an anti-platelet agent, clopidogrel (SR 25990 C) on the inner capsule].
    Hanaoka T
    Nihon Geka Gakkai Zasshi; 1994 Oct; 95(10):775-85. PubMed ID: 7823899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.